Abstract 334P
Background
Compared to global figures, breast cancer mortality to incidence ratio is worst in Sub Saharan Africa where about 80% of patients present with locally advanced and metastatic disease at diagnosis. In Cameroon, breast cancer is the commonest cancer with 4,170 cases recorded each year constituting 20.1% of all cancers diagnosed. Late disease presentation is attributed to poor awareness, absence of organized early detection programs, and inadequate facilities for accurate and timely diagnosis and treatment. Our objective was to investigate the role that nurses involved in cervical cancer screening/prevention can play in early detection of breast cancer in Cameroon.
Methods
The nurses involved in cervical cancer screening/prevention in a large faith-based healthcare organization called the Cameroon Baptist Convention Health Services (CBCHS) were trained to do clinical breast exams (CBE) for women aged 21 years and over, and also trained on breast tissue collection for pathology processing and examination. Clients with abnormal breast findings were provided Fine Needle Aspirations (FNA), TruCut biopsies or referred for ultrasound and/or mammography depending on the clinical presentation.
Results
Between January 2020 and December 2022, a total of 16,038 women age range (14-99) years were provided CBE with a mean and median age of 40.4 and 39, respectively. Among these, 750 (4.7%) had abnormal findings. Among those with abnormal findings, 397(52.9%) had breast masses for which 213 (53.7%) had TruCut biopsies and FNA and the others were either referred or had previously established diagnosis. From the 213 Tru-Cut biopsies and FNA’s done, 76 (35.7%) showed a pathology diagnosis of invasive breast cancer while the others showed: acute mastitis 3 (2.9%), fibroadenoma 25 (11.7%), benign mass 83 (39.0%), non-diagnostic 12 (5.6%) and other diagnosis 19 (8.9%).
Conclusions
Nurses can play a key role in early detection of breast cancer if they are trained, and this can greatly reduce the number of women seen with late stage disease and also reduce mortality rates.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
303P - Differential prognostic role of PDGFRA alterations in breast cancer subtypes
Presenter: Panagiotis Vlachostergios
Session: Poster session 02
304P - Generalizability of 313-SNP PRS for breast cancer risk in non-European ancestries
Presenter: Helen Shang
Session: Poster session 02
305P - Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer
Presenter: Sora Kang
Session: Poster session 02
307P - Identifying new biological subgroups of triple-negative breast cancer using next-generation integrative clustering pipeline
Presenter: Xixuan Zhu
Session: Poster session 02
308P - Regression-based deep-learning predicts breast cancer recurrence risk score from pathology slides
Presenter: Omar El Nahhas
Session: Poster session 02
310P - Longitudinal evaluation of circulating tumour DNA in early breast cancer using a plasma-only methylation-based assay
Presenter: Mitchell Elliott
Session: Poster session 02
311P - Multinational survey study assessing genetic testing and counselling among patients (pts) with breast cancer (MAGENTA): Results on the genetic counselling experience
Presenter: Ranjit Kaur
Session: Poster session 02
312P - Prediction model of breast cancer patient’s neoadjuvant treatment outcome using breast cancer organoids cultured from core needle biopsies
Presenter: Dong Woo Lee
Session: Poster session 02